Psychedelic drugs such as psilocybin, ayahuasca, ketamine, MDMA, and LSD show therapeutic potential for conditions like PTSD, depression, existential distress, and addiction. Unlike conventional psychoactive drugs, psychedelics are experiential therapies whose value lies in the subjective experiences they induce. Some argue that trainee psychedelic therapists should undergo firsthand psychedelic experience to fully understand these effects. The authors question this, finding the claimed epistemic benefits not uniquely compelling and the evidence for their contribution to training insufficient. They conclude that requiring trainees to take psychedelics is not ethically legitimate, though permitting voluntary experience may be acceptable given potential epistemic benefit cannot be ruled out.
Psychedelic medicine is re-emerging as a therapeutic modality, particularly for terminally ill patients experiencing existential distress near the end of life. This distress involves demoralization and a sense of meaninglessness, impairing one's ability to create or realize meaning. Psychedelic experiences, in contrast, often produce profound and lasting meaning. The essay examines whether meaning is a proper concern for healthcare and highlights implications of psychedelic medicine. It concludes by urging bioethics to recognize itself as a meaningful cultural discourse shaping the future of medicine, psychedelics, and what it means to be human.